Literature DB >> 25881195

The impact of ischemic postconditioning on ischemic skin flap injuries.

Lin Huang1.   

Abstract

UNLABELLED:  Ischemic postconditioning (IPOC) is a useful manipulation to reduce the undesirable effects of ischemia-reperfusion (IR) injury. The effects of IPOC were studied in an axial pattern skin flap model.
METHODS: The skin flaps of 40 rabbits were randomly divided into four groups. Ischemic postconditioning was performed using six 10-second cycles of repeated ischemia/reperfusion periods. The animals were al- located into four groups: group 1 (control); group 2 (ischemia); group 3 (postconditioning); group 4 (postconditioning 10 minutes later). Flap viability was assessed 1 week after the operation. The surviving flap area was recorded as a percentage of the entire flap area. Fisher's least significant difference (LSD) test was used for statistical analysis among different groups to evaluate the effects of ischemic preconditioning against ischemia.
RESULTS: The mean ± SD of surviving flap areas for groups 1, 2, 3, and 4 were 97.86 ± 0.62, 31.64 ± 1.04, 48.95 ± 0.82, and 30.01 ± 1.12, respectively. Statistical difference did not exist between group 2 and 4, but they were statistically different (P < 0.05) when compared to group 1 or group 3.
CONCLUSION: Ischemic postconditioning has a protective effect on ischemic flaps, but post- conditioning should be performed just after the ischemic event. .

Entities:  

Year:  2011        PMID: 25881195

Source DB:  PubMed          Journal:  Wounds        ISSN: 1044-7946            Impact factor:   1.546


  2 in total

1.  The role of shear stress on cutaneous microvascular endothelial function in humans.

Authors:  Gary J Hodges; Desmond G Stewart; Paul J Davison; Stephen S Cheung
Journal:  Eur J Appl Physiol       Date:  2017-10-06       Impact factor: 3.078

2.  What happened if various kinds of postconditioning working on the preconditioned ischemic skin flaps.

Authors:  Lin Huang
Journal:  PLoS One       Date:  2013-09-12       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.